The Technical AnalystExchange: XETRA Sector: Life Sciences Tools & Services Industry: Drug Manufacturers—Specialty & Generic
Evotec SE Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.59% €9.90
Europe/Berlin / 2 mai 2024 @ 17:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 750.95 mill |
| EPS: | -1.030 |
| P/E: | -9.61 |
| Earnings Date: | Aug 09, 2023 |
| SharesOutstanding: | 176.95 mill |
| Avg Daily Volume: | 1.260 mill |
| RATING 2024-05-02 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.61 | sector: PE 140.12 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.25x |
| Company: PE -9.61 | industry: PE 39.15 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€11.52 (16.43%) €1.626 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
€ 9.31 - 10.64 ( +/- 6.67%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €9.90 (1.59% ) |
| Volume | 2.64 mill |
| Avg. Vol. | 1.260 mill |
| % of Avg. Vol | 209.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVT.DE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EVT.DE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.